Venus Remedies Get Marketing Nod For Six Chemotherapy Drugs

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Venus Remedies get marketing nod for six Chemotherapy Drugs

ri-calendar-2-lineOct 16, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

Venus Remedies, a global oncology drug provider, has received marketing approval for six crucial chemotherapy drugs in the Philippines, marking a significant stride in the ASEAN region. These approvals include bortezomib, cisplatin, doxorubicin, docetaxel, fluorouracil, and paclitaxel, solidifying Venus Remedies' position in the dynamic $420 billion pharmaceutical market of the Philippines. With this achievement, Venus Remedies now holds 525 marketing approvals for its oncology products across 76 countries.

 

Saransh Chaudhary, CEO of Venus Medicine Research Centre, emphasized the company's goal of becoming the premier oncology medicine supplier from India in Southeast Asia. The Philippines' market for cancer drugs, which is projected to grow at a CAGR of 8.7% by 2025, provides immense opportunities for Venus Remedies to expand its operations in the Asia-Pacific region.

 

Additionally, Venus Remedies' oncology wing has received marketing authorization for the chemotherapy drug oxaliplatin in Myanmar, furthering the company's footprint in the ASEAN region. These achievements underscore Venus Remedies' commitment to delivering advanced cancer therapies globally.

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Stock chartMutual Fund

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025

0 people read

8 mins read . Aug 18, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions